Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: A meta-analysis of randomized controlled trials

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Huang, Xiaojie ^a   Xu, Yuanlong ^a,b   Yang, Qiuying ^c   Chen, Jieqing ^c   Zhang, Tong ^a   Li, Zaicun ^a   Guo, Caiping ^a   Chen, Hui ^c   Wu, Hao ^a   Li, Ning ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Longtan Hospital of Guangxi Province   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; LOPINAVIR; RITONAVIR;

ADULT; BIRTH WEIGHT; BLOOD; FACTUAL DATABASE; FEMALE; HIV INFECTIONS; HUMAN; META ANALYSIS; NEWBORN; PREGNANCY; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BIRTH WEIGHT; CHOLESTEROL; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LOPINAVIR; PREGNANCY; PREMATURE BIRTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; TREATMENT OUTCOME;

EID: 84923337066     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08528     Document Type: Article

References (33)

1. Palella, F. J. Jr et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338, 853-860 (1998).
2. Schackman, B. R. et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44, 990-997 (2006).
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/guidelines. (Accessed 30th August 2014)
4. Thompson, M. A. et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308, 387-402 (2012).
5. Williams, I. et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013). HIV Med 15 Suppl 1,1-85 (2014).
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision.). Available at: http://www.who.int/hiv/pub/guidelines/. (Accessed 30th August 2014)
7. Walmsley, S. et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346, 2039-2046 (2002).
8. Ortiz, R. et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22, 1389-1397 (2008).
9. Delfraissy, J. F. et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22, 385-393 (2008).
10. Johnson, M. A. et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. JAIDS - J Acq Imm Def Syndr 43, 153-160 (2006).
11. Smith, K. Y. et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23, 1547-1556 (2009).
12. Molina, J. M. et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372, 646-655 (2008).
13. Eron, J. Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavirritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 368, 476-482 (2006).
14. Sierra-Madero, J. et al. Prospective, randomized, open label trial of efavirenz vs. lopinavir/ritonavir in HIV+ treatment-naive subjects with CD4+200 cell/mm3 in Mexico. JAIDS - J Acq Imm Def Syndr 53, 582-588 (2010).
15. Cohen, C. et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 21, 1683-1692 (2005).
16. Zajdenverg, R. et al. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. JAIDS - J Acq Imm Def Syndr 54, 143-151 (2010).
17. Johnson, M. et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19, 685-694 (2005).
18. De Meyer, S. et al. Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomized, controlled, phase III study (TITAN). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney 2007. Abstract WEPEB038.
19. Roberts, S. S. et al. Lopinavir/ritonavir in pregnancy. JAIDS - J Acq ImmDef Syndr 51, 456-461 (2009).
20. Senise, J. et al. Low-birth weight and pre-term delivery in relation to lopinavir/ritonavir use in pregnancy. J Am Infect Dis 4, 209-214 (2008).
21. de Vincenzi, I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomized controlled trial. Lancet Infect Dis 11, 171-180 (2011).
22. Azria, E. et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antiviral Ther 14, 423-432 (2009).
23. Peixoto, M. F. et al. Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. Braz J Infect Dis 15, 253-261 (2011).
24. Villatoro, C. M. et al. Highly Active Antiretroviral Treatment (HAART) for the Prevention of HIV Mother to Child Transmission (PMTCT) at Roosevelt Hospital's Infectious Diseases Clinic in Guatemala: The Role of (LPV/r) Standard Dose. World J AIDS 2, 259-264 (2012).
25. Shapiro, R. L. et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362, 2282-2294 (2010).
26. Wolf, E. et al. Similar virological response rates for ART-naive subjects starting KVX + LPV/r or TVD + LPV/r: Data from the prospective observational STAR cohort. J Int AIDS Society 11 (Suppl 1), 7 (2008).
27. Eccleston, K. J., Bambumba, A., Babu, C. S., Ahmed, S. & Lee, V. Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting: the TEAL study. J Int AIDS Society 11 (Suppl 1), 79 (2008).
28. Massad, L. S. et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 18, 281-286 (2004).
29. Morris, A. B. et al. Multicenter review of protease inhibitors in 89 pregnancies. JAIDS-J Acq Imm Def Syndr 25, 306-311 (2000).
30. Centers for Disease Control and Prevention (CDC). Preterm singleton births - United States, 1989-1996. MMWR Morb Mortal Wkly Rep 48, 185-189 (1999).
31. Kourtis, A. P. et al. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003. AIDS 20, 1823-1831 (2006).
32. Pasley, M. V., Martinez, M., Hermes, A., d'Amico, R. & Nilius, A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev 15, 38-48 (2013).
33. Altman, D. G. & Bland, J. M. Statistics Notes: Interaction revisited: the difference between two estimates. Bri Med J 326, 219 (2003).